MOESM7 of Genetic dynamics in untreated CLL patients with either stable or progressive disease: a longitudinal study
Alice Ramassone(University of Chieti-Pescara), Rosa Visone(University of Chieti-Pescara), Manuela Ferracin(University of Ferrara), Elena Saccenti(University of Ferrara), Francesco Autore(Agostino Gemelli University Polyclinic), Luca Laurenti(Sapienza University of Rome), Stefano Volinia(University of Ferrara), Sara Pagotto(University of Chieti-Pescara), Thomas J. Kipps(University of California San Diego), Laura Lupini(University of Ferrara), Idanna Innocenti(Università Cattolica del Sacro Cuore), Felice Pepe(University of Chieti-Pescara), Renato Mariani‐Costantini(University of Chieti-Pescara), Veronica Balatti(The Ohio State University Wexner Medical Center), Alessio Basti(University of Chieti-Pescara), Angelo Veronese(University of Ferrara), Shimaa Soliman(Northwestern University), Laura Marzetti(University of Chieti-Pescara), Massimo Negrini(University of Ferrara), Cristian Bassi(University of Ferrara), Andrea D’Argenio(University of Chieti-Pescara), Laura Z. Rassenti(University of California San Diego)
Cited by 0
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k